Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01664130 · ClinicalTrials.gov registry record · NA

High-Dose Stereotactic Radiation for Prostate Cancer

A NA study, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
NA
Development phase
35
Enrollment target

NCT01664130 is a NA study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 35 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01664130, a NA study, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
NA
Development phase
35 participants
Enrollment target

Study Summary

This clinical trial studies high-dose stereotactic body radiation therapy (SBRT) in treating patients with low-, intermediate-, or high-risk localized prostate cancer. SBRT may be able to send x-rays directly to the tumor and cause less damage to normal tissue

Interventions

  • OTHER laboratory biomarker analysis
  • RADIATION stereotactic body radiation therapy
  • PROCEDURE quality-of-life assessment

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2012-07
Est. Completion 2017-01-12
Phase NA

Sponsor

Case Comprehensive Cancer Center

407 total trials

What the Registry Record Tells You About NCT01664130

The ClinicalTrials.gov registry entry for NCT01664130 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.

NCT01664130 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01664130 about?

NCT01664130 is a clinical study titled "High-Dose Stereotactic Radiation for Prostate Cancer". This clinical trial studies high-dose stereotactic body radiation therapy (SBRT) in treating patients with low-, intermediate-, or high-risk localized prostate cancer. SBRT may be able to send x-rays directly to the tumor and cause less damage to normal tissue

What is the current status of trial NCT01664130?

This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2012-07. Estimated completion is 2017-01-12.

What interventions are being tested in trial NCT01664130?

The interventions under investigation include: laboratory biomarker analysis (OTHER), stereotactic body radiation therapy (RADIATION), quality-of-life assessment (PROCEDURE).

Who is sponsoring clinical trial NCT01664130?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.